Lecanemab treatment for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 85 years old.
- You have completed at least 3 years of schooling (elementary school or higher).
- You either have mild Alzheimer’s (confirmed by a doctor and a brain scan showing amyloid plaques) or mild memory problems (MCI) with a positive amyloid scan.
- You do not have a history of stroke, brain conditions like Parkinson’s or epilepsy, or serious illnesses like severe liver, kidney, or heart disease.
- You are not taking blood thinners (like warfarin) and have no metal implants that would prevent an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.